---
title: "XYF: FY2025 delivered strong growth and returns, but 2Q2026 net income dropped sharply on margin pressure"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296768741.md"
description: "FY2025 saw $209M net income, 20% ROE, and 17.6% EPS growth, with 6.7M active borrowers and $18.7B in loans facilitated. Capital returns accelerated, but 2Q2026 net income fell sharply due to margin compression and higher credit provisions.Original document: X Financial [XYF] Slides Release — Aug. 24 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-24T10:04:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296768741.md)
  - [en](https://longbridge.com/en/news/296768741.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296768741.md)
generator: "portal-rs"
---

# XYF: FY2025 delivered strong growth and returns, but 2Q2026 net income dropped sharply on margin pressure

FY2025 saw $209M net income, 20% ROE, and 17.6% EPS growth, with 6.7M active borrowers and $18.7B in loans facilitated. Capital returns accelerated, but 2Q2026 net income fell sharply due to margin compression and higher credit provisions.

Original document: X Financial \[XYF\] Slides Release — Aug. 24 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [XYF.US](https://longbridge.com/en/quote/XYF.US.md)

## Related News & Research

- [X Financial (NYSE:XYF) Posts Quarterly Earnings Results, Beats Expectations By $0.35 EPS](https://longbridge.com/en/news/296778384.md)
- [X Financial Q2 FY26 net income drops 91.1% YoY to RMB 47 million; revenue falls 56.3% to RMB 993.6 million](https://longbridge.com/en/news/296766616.md)
- [DE: 3Q 2026 saw sales and profit growth, but FY 2026 guidance signals industry headwinds](https://longbridge.com/en/news/296475895.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**